Published in Clinicoecon Outcomes Res on July 14, 2010
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 5.27
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology (1990) 4.43
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology (2010) 4.19
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol (1999) 3.65
Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med (1999) 3.38
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
The burden of hepatitis C in the United States. Hepatology (2002) 3.16
Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology (1998) 3.00
Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut (1999) 2.98
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology (1999) 2.67
45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med (2000) 2.66
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology (2002) 2.26
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med (2001) 2.12
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med (1993) 1.89
Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology (1999) 1.84
Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol (2010) 1.84
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol (2003) 1.83
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ (2001) 1.67
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol (2005) 1.53
Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis (2009) 1.53
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol (1992) 1.50
Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ (2009) 1.42
Monitoring of viral levels during therapy of hepatitis C. Hepatology (2002) 1.37
The effects of HCV infection and management on health-related quality of life. Hepatology (2007) 1.36
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol (2004) 1.33
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol (2005) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Fatigue in patients with chronic hepatitis C. J Viral Hepat (2002) 1.30
Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat (2002) 1.22
Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci (1996) 1.20
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther (2002) 1.01
Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver (1993) 1.00
Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care (2005) 1.00
Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis (1999) 0.97
Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care (2009) 0.96
Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther (2002) 0.95
What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev (2004) 0.90
Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis (2006) 0.87
Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat (2008) 0.85
A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther (2003) 0.83
When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia (2008) 0.83
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med (2000) 0.82
Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology (2006) 0.81
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients. N Engl J Med (2004) 0.76
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology (1999) 1.54
Determination by Widal agglutination of the baseline titre for the diagnosis of typhoid fever in two Nigerian states. Scand J Immunol Suppl (1992) 0.98
The use of highly active antiretroviral therapy for the prevention of mother-to-child transmission of the human immunodeficiency virus in Nigeria. J Obstet Gynaecol (2010) 0.97
Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses (2010) 0.92
Sex and reproduction among HIV-infected people in Maiduguri, Nigeria. J Obstet Gynaecol (2007) 0.87
Cervical dysplasia in HIV infected women in Maiduguri, Nigeria. J Obstet Gynaecol (2005) 0.84
The value of highly active antiretroviral therapy in the prevention of mother-to-child transmission of HIV. J Obstet Gynaecol (2007) 0.84
Helicobacter pylori infection in Nigerians with dyspepsia. Ghana Med J (2013) 0.83
Relation between some haematological abnormalities, degree of immunosuppression and viral load in treatment-naïve HIV-infected patients. East Mediterr Health J (2013) 0.82
Fine needle aspiration cytology diagnosis of liver diseases in the University of Maiduguri Teaching Hospital, Maiduguri. Afr J Med Med Sci (2004) 0.81
The effectiveness of outreach testing for hepatitis C in an immigrant Pakistani population. Epidemiol Infect (2011) 0.81
Mantoux reaction in patients with HIV-related pulmonary tuberculosis in Maiduguri, Nigeria. Afr J Med Med Sci (2005) 0.80
Should absolute lymphocyte count be used as a surrogate marker for CD4+ count in patients with HIV/AIDS? Afr J Med Med Sci (2006) 0.79
Impact of health education on prostitutes' awareness and attitudes to acquired immune deficiency syndrome (AIDS). Public Health (1988) 0.78
Incidence of community-acquired meticillin resistant Staphylococcus aureus hand infections in Tayside, Scotland: a guide to appropriate antimicrobial prescribing. J Hand Surg Eur Vol (2010) 0.75
Prevalence of human immunodeficiency virus (HIV) infection in Borno State of Nigeria. East Afr Med J (1988) 0.75
Carcinoma of prostate presenting as dysphagia. Br J Urol (1987) 0.75
Spontaneous bacterial peritonitis prophylaxis in the era of healthcare associated infection. Gut (2012) 0.75